Vanguard Group Inc Mi Nk Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INKT
# of Institutions
29Shares Held
848KCall Options Held
0Put Options Held
0-
Longbow Finance Sa Lutry, V8167KShares$84,9990.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny107KShares$54,4100.0% of portfolio
-
Geode Capital Management, LLC Boston, MA98KShares$49,9700.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$44,4690.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL51.7KShares$26,3810.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $17.2M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...